The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial anti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:iScience
Autores principales: Jasenosky, Luke D., Cadena, Cristhian, Mire, Chad E., Borisevich, Viktoriya, Haridas, Viraga, Ranjbar, Shahin, Nambu, Aya, Bavari, Sina, Soloveva, Veronica, Sadukhan, Supriya, Cassell, Gail H., Geisbert, Thomas W., Hur, Sun, Goldfeld, Anne E.
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6831822/
https://ncbi.nlm.nih.gov/pubmed/31402258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.isci.2019.07.003
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares